Considering the well-established, TLR2/4-dependent function of biglycan in NF-κB signaling, the fact that TLRs have been linked to tumorigenesis of multiple tumor types (191, 192), and the known implications of the NF-κB pathway in the development of chemotherapy resistance in cancers (193, 194), it is convincing that biglycan may promote resistance mechanisms by regulating the NF-κB pathway. Here, TLR2 is linked to neoplasm.